KNOXVILLE, Tenn. -- (BUSINESS WIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala of St. Luke's University Health Network will present clinical data on Provectus’ PV-10 preparation for the treatment of melanoma at the 10th European Association of Dermato-Oncology (EADO) Congress in Vilnius, Lithuania. The Congress runs from May 7-10, 2014, and Dr. Agarwala’s presentation is scheduled for the first day of the Congress, Wednesday, May 7.
Dr. Craig Dees, PhD, CEO of Provectus, said, "Provectus is happy to see our colleague Dr. Agarwala sharing what he and his team at St. Luke’s have learned about PV-10 in the treatment of melanoma with the members of EADO at this year’s Congress.”
PV-10, a 10% solution of Rose Bengal that is currently being examined as a novel cancer therapeutic, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, minimizing potential for systemic side effects.
About the European Association of Dermato-Oncology
The European Association of Dermato-Oncology is an independent non-profit organization dedicated to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research. EADO has a European and international membership of dermatologists, oncologists and clinical as well as basic research scientists interested in the field of Dermato-Oncology and offers coordination and support of projects of the respective national skin cancer groups. For additional information about EADO please visit the website at http://www.eado.org/.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.